
Daily Derm Times: May 13, 2025
Key Takeaways
- IL-13 and IL-31 inhibitors provide distinct yet complementary mechanisms for atopic dermatitis management, enhancing treatment strategies.
- JAK inhibitors in vitiligo management show promising efficacy and safety, with potential for combination therapies.
Catch up on dermatology news, highlights, and insights from the past 24 hours.
To stay up-to-date with the latest dermatology news, sign up to receive our
Experts Look Ahead to the Advancements in AD Research
To hear more about AD advancements from Shahriari and Lio in person, register to attend the Revolutionizing Atopic Dermatitis Conference 2025 in Nashville, Tennessee, on June 6 and 7.
What to Know When Targeting IL-13 vs IL-31 in Atopic Dermatitis
Raj Chovatiya, MD, PhD, MSCI, discusses how IL-13 and IL-31 inhibitors represent distinct yet complementary mechanisms in the management of atopic dermatitis.
New Meta-Analysis Supports Targeted Vitiligo Therapies
Explore the promising role of JAK inhibitors in vitiligo management, highlighting efficacy, safety, and potential combination therapies for enhanced results.
New Survey Confirms Acne Patients Have More Trust in Clinicians than Social Media Influencers
Even with the recent rise of social media guidance, patients still trust dermatologists over social media influencers for acne treatment.
Botanical-Based Nutraceutical Improves Acne
Discover how a novel nutraceutical significantly improves mild to moderate acne in a 12-week clinical trial, offering a holistic approach to skin health.
Dual Inhibitor TRIV-509 Shows Promise for Rapid Improvement in Atopic Dermatitis
Researchers reveal TRIV-509, a novel monoclonal antibody, shows promise in rapidly improving atopic dermatitis by restoring skin barrier integrity and reducing inflammation.
Tyk2 Inhibition Prevents Islet Inflammation and Delays Type 1 Diabetes Development in Mice
New research reveals a promising strategy to slow type 1 diabetes progression by targeting inflammation with an existing psoriasis drug.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


















